NEJM 2023: 10.1056/NEJMoa2301972 Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity)
Tai J, Liu W, Li Y, Li L, Hlscher C
Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
These drugs have also been demonstrated to aid in weight loss by decreasing food intake and raising satiety
TRANSCEND-T2D-1: Retatrutide Phase 3 Diabetes Results (March 2026) First Phase 3 retatrutide trial in type 2 diabetes 16.8% weight loss and -2.0% A1C at 12 mg over 40 weeks
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial